Nexit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nexit

What is Nexit: Definition, Class, and Purpose

Property Description
Active ingredient Hydroxyzine
Form Tablet, Capsule, Syrup, Injectable Solution
Pharmacological class First-Generation Antihistamine, Anxiolytic
Common purpose Relief of itching, reduction of tension, antiemetic
Origin Synthetic organic compound

Nexit is a prescription medication containing the active ingredient Hydroxyzine, a synthetic compound belonging to the piperazine chemical family. It is officially categorized as a first-generation antihistamine that simultaneously exhibits significant anxiolytic (anti-anxiety) and sedative properties, a characteristic supported by pharmacological studies confirming its efficacy in calming the nervous system.

Unlike newer, second-generation antihistamines, Nexit is capable of readily affecting the Central Nervous System (CNS). This distinction provides a dual therapeutic benefit: it addresses symptoms driven by histamine release while also offering a profound calming effect. The medication is utilized in clinical settings due to its pharmacological classification as an H1 receptor inverse agonist, meaning it actively works to block the effects of histamine throughout the body.

Composition and Available Forms of Nexit

The active compound, Hydroxyzine, is available in various forms to suit different needs and routes of administration, most commonly as the hydrochloride or pamoate salt. Nexit is a single-ingredient product offered as oral tablets, capsules, syrup, and oral solution for oral delivery, as well as an intramuscular (IM) injectable solution used for specialized applications. This variety ensures that the product can be administered effectively according to the required speed of action and patient condition.

The overall purpose of Nexit is to alleviate severe itching and reduce general nervous tension. Its histamine blockade function effectively mitigates the body's allergic response. Simultaneously, the drug's influence as a CNS depressant diminishes central nervous system excitability, which helps to calm the patient. Furthermore, the drug possesses known antiemetic activity, meaning it also generally helps to control feelings of nausea and the urge to vomit.

Regulatory References

  1. NIH LiverTox: Hydroxyzine
  2. DailyMed Label: Hydroxyzine Hydrochloride
  3. MedlinePlus Drug Information: Hydroxyzine

What side effects are possible with Nexit?

Possible Side Effects and Safety Information

Nexit's safety profile, as documented in official regulatory sources, involves adverse reactions primarily related to its properties as a first-generation antihistamine and CNS depressant. These effects are formally classified by frequency and grouped into System-Organ-Classes (SOC).


Frequency-Classified Adverse Reactions

Classification Examples of Effects
Very Common Sedation, Dry Mouth
Common Fatigue, Dizziness, Headache
Rare Tachycardia, Disorientation, Urinary Retention
Frequency Not Known QT-interval prolongation, Torsade de Pointes
  • System-Organ-Classes involved include Nervous System Disorders, Cardiac Disorders, and Gastrointestinal Disorders. Sedation, a very common effect, is related to the Nervous System and may be most noticeable at the start of treatment.

Serious Safety Considerations

The most significant safety restriction relates to Cardiac Disorders. Regulatory documents highlight the risk of QT-interval prolongation and the potential for a severe heart rhythm abnormality known as Torsade de Pointes (Frequency Not Known). This is a critical factor influencing its safe use.

Nexit is contraindicated in patients with a known pre-existing prolonged QT interval or other uncorrected cardiac risk factors. Additionally, severe skin reactions, such as Acute Generalized Exanthematous Pustulosis (AGEP), are documented as rare postmarketing events.

Population-Specific Notes

The official label specifies caution for certain patient populations. Older adults are generally at a greater risk for adverse reactions, including confusion and sedation, and often require lower dosage consideration. Renal and hepatic impairment also necessitate adjusted use due to altered drug clearance, as explicitly stated in regulatory information.

Overdose and Emergency Response

A Nexit (Hydroxyzine) overdose primarily affects the Central Nervous System (CNS) and the Cardiovascular System. Officially documented overdose presentations include a range of symptoms, most commonly hypersedation, stupor, and convulsions. Gastrointestinal effects such as nausea and vomiting, along with signs of CNS excitation like shaking, may also be present.

Overdosage carries a significant risk of severe, life-threatening cardiac effects. Regulatory information explicitly warns of the potential for QT prolongation and the serious arrhythmia Torsade de Pointes (TdP), which have been observed with excessive blood concentrations. Convulsions are reported more frequently in children compared to adults.

Due to the severity of these potential outcomes, immediate medical attention must be sought for any suspected overdose. Emergency help is specifically required if cardiac symptoms occur, such as palpitations, trouble breathing, or loss of consciousness. This immediate action is critical.

The management strategy described in regulatory documents centers on general supportive care and specific monitoring. Because no specific antidote is available, physicians are directed to perform procedures such as immediate gastric lavage and initiate ECG monitoring to assess for cardiotoxicity. The use of certain vasopressors may be indicated for hypotension, but the regulatory guidance specifically advises against the use of epinephrine.

Therapeutic Uses of Nexit

What Nexit Treats: Main Uses and Benefits

The active ingredient in Nexit, Hydroxyzine, is commonly used in therapeutic domains for managing symptoms across distinct clinical contexts. This medication is applicable within clinical settings that involve acute or disruptive symptom patterns.

Nexit is relevant for easing symptoms associated with certain conditions, including the symptomatic relief of nervous tension and anxiety associated with psychoneurosis, and is applied to address intense pruritus (itching) and related skin discomfort. It is also used in procedural care for its sedative effects and for addressing nausea and vomiting. The drug is applicable across domains where additional symptomatic support is needed.

“Nexit is relevant in contexts marked by increased discomfort or tension, supporting the relief of symptoms that interfere with daily comfort.”

It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability during periods of heightened symptoms.


Quick Fact: Symptom Management for Pruritus and Tension

Nexit is commonly used when symptoms intensify and supportive relief is needed for: severe allergic itching, pre-procedural anxiety, and situational nervous tension, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Nexit?

Nexit (Hydroxyzine) use is defined by specific population eligibility rules established in regulatory documents, with several patient groups having absolute contraindications.

Population Status Regulatory Rule
Contraindicated Populations Patients with a known prolonged QT interval or those with uncorrected risk factors for Torsade de Pointes. Individuals with known hypersensitivity to hydroxyzine, its active metabolite cetirizine, or levocetirizine.
Pregnancy and Lactation Contraindicated in early pregnancy and during late pregnancy/labor. Use is not recommended while breastfeeding due to drug excretion into human milk.
Age and Organ Function Use in older adults (ge 65 years) is generally not recommended due to increased side effect risks; a lower maximum dose is mandated if used. Patients with renal impairment (CrCl le 50 mL/min) or hepatic impairment require a mandatory dose reduction for use.
Conditional Use Caution is required in patients with bladder neck obstruction or angle-closure glaucoma due to the medicine's properties.

Regulatory criteria permit use in adults and children for approved indications, provided no absolute contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nexit, which contains the active ingredients bempedoic acid and ezetimibe, can interact with other medicines, requiring careful monitoring or dose adjustments. Interactions are primarily related to the presence of its two active components.

Interacting Medicinal Product Categories and Specific Drugs

  • Statins: Significant interactions occur with certain HMG-CoA reductase inhibitors (statins). Concomitant use with simvastatin doses greater than 20 mg and pravastatin doses greater than 40 mg should be avoided due to the potential for increased exposure to the statin and an elevated risk of muscle-related side effects, such as myopathy or rhabdomyolysis. Lower doses of these statins may be used with caution.
  • Cyclosporine: Co-administration with cyclosporine may increase the exposure of both Nexit components and cyclosporine itself. Monitoring of cyclosporine concentrations is recommended.
  • Bile Acid Sequestrants (e.g., cholestyramine): These medicines can reduce the absorption of Nexit. To prevent this effect, Nexit must be administered either at least two hours before or at least four hours after a bile acid sequestrant.

Other Interaction-Related Constraints

  • Mechanism: Bempedoic acid (one component of Nexit) is known to inhibit the activity of the OATP1B1 and OATP1B3 transporters, which is the primary mechanism for the increased exposure of co-administered statins.
  • Tendon Rupture Risk: The risk of tendon rupture, a documented side effect, may be increased when Nexit is used in patients also taking corticosteroid or fluoroquinolone antibiotics. This highlights a critical, condition-specific interaction that necessitates careful clinical consideration.

Mechanism of Action

Nexit functions via a dual-mechanism approach to modulate systemic cholesterol pathways, targeting both hepatic synthesis and intestinal absorption.


Hepatic Cholesterol Synthesis Inhibition

This domain involves the active metabolite of Bempedoic Acid inhibiting the enzyme adenosine triphosphate-citrate lyase (ACL) within the liver. Modifying this early molecular step in hepatic cholesterol production reduces the amount of intracellular cholesterol. This reduction triggers a homeostatic upregulation of LDL receptors on the liver cell surface, increasing the subsequent clearance of low-density lipoprotein cholesterol (LDL-C) from the circulation.


Intestinal Cholesterol Absorption Modulation

The second domain, mediated by Ezetimibe, acts to reduce the absorption of cholesterol from the small intestine. This is achieved by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter protein. This mechanism attenuates the rate of cholesterol transfer from the intestinal lumen, influencing the flux of unesterified cholesterol to the hepatic portal system, which ultimately results in a reduction of circulating LDL-C concentration.

Dosage and Administration Information

How Nexit is Used

The usage of Nexit, containing Hydroxyzine, is determined by specific administration routes and dosage schedules. The medication is primarily intended for oral administration, available as tablets, capsules, and syrup/solution, but also has an intramuscular (IM) injectable solution. The injectable form is strictly limited to IM use and must not be administered intravenously or subcutaneously.

Official Dosing Patterns

Dosing regimens are established based on the clinical context. For symptomatic relief of pruritus, the typical starting dose is 25 mg. In contexts requiring anxiety relief, the total daily dose is typically 50 mg to 100 mg, generally administered in divided doses up to four times per day. When used for pre- or post-operative sedation, Nexit is usually given as a single dose of 50 mg to 100 mg orally, or 25 mg to 100 mg via the IM route.

Contextual and Population Adjustments

Nexit can be taken with or without food. For the oral liquid form, the solution must be shaken well before use and measured accurately.

Mandatory dose adjustments are required for specific populations. The maximum daily dose for older adults is typically restricted, such as 50 mg/day. Furthermore, the total daily dose must be reduced in the presence of hepatic impairment or moderate to severe renal impairment, often by 33% to 50% respectively. The use for anxiety has not been systematically evaluated in studies longer than four months, and continued application should be periodically reassessed.

Recent Clinical Evidence

Research evidence / Overview of studies for Nexit

Evidence for use in Anxiety and Nervous Tension

Research has examined the use of Nexit in studies exploring how symptoms change over time related to anxiety and nervous tension, often focusing on conditions characterized by fluctuating or episodic manifestations. These evaluations have primarily been conducted through short-term randomized controlled trials (RCTs) in adult populations. The studies explored outcomes describing episodic or acute changes, including measurements in standardized scores used to measure anxiety severity (such as the Hamilton Anxiety Rating Scale or HAM-A).

Findings describe patterns observed in the studies in anxiety symptom scores. This research provides insight into short-term changes over defined time intervals. However, the follow-up durations were limited, typically lasting between four and twelve weeks. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding consistent use beyond a few months.


Evidence for use in Pruritus (Itching) and Allergic Conditions

The use of Nexit in studies exploring how symptoms change over time for pruritus (itching) associated with conditions linked to inflammatory or irritative states has been evaluated in numerous clinical trials and systematic reviews. Studies explored populations including adults and children presenting with chronic itching. Primary outcomes research examined were measurements of itch severity and how these correlated with outcomes reflecting daily functioning or activity level, particularly sleep quality.

While there is substantial evidence regarding its short-term and acute use, comparative evidence is lacking against all newer generation medications. Evidence quality varies across studies, and the results apply only to the populations studied and the specific causes of itching that were included in the research. Research for older adults has limited information for long-term outcomes, and data describing the drug's use in this population is limited.


What is Still Uncertain About the Research Base

Long-term effects are not fully established across all indications, as follow-up durations were limited in many pivotal trials. The evidence quality varies across studies, with some older trials having sample sizes were modest or methodological limitations. Furthermore, comparative evidence is lacking in certain areas, particularly when comparing Nexit against the newest available treatments for anxiety and chronic itching. Overall, the research highlights what is known — and what is still uncertain — about the drug's use, particularly for maintenance or long-duration treatment protocols.

Key Studies & References

  1. Hydroxyzine Hydrochloride Tablet, film coated - DailyMed (Official Labeling)
  2. Hydroxyzine (LiverTox: Clinical and Research Information on Drug-Induced Liver Injury)

Frequently Asked Questions (FAQ)

Common questions about Nexit (FAQ)


Q: Is Nexit the same kind of medicine as other drugs that treat similar conditions?

According to official product information, Nexit (Hydroxyzine) is categorized as a first-generation antihistamine. This chemical classification differentiates it from other medicines used for similar conditions, such as second-generation antihistamines. Its action involves blocking histamine and decreasing activity in certain subcortical regions of the central nervous system.


Q: Can Nexit be used for purposes other than the main use listed?

The FDA-approved uses for Nexit are the symptomatic relief of anxiety and tension, the symptomatic relief of itching (pruritus) due to allergic conditions, and use as a sedative premedication prior to and following general anesthesia. Regulatory documents solely define these approved uses and do not describe use for other purposes.


Q: How quickly should I expect to notice anything after starting Nexit?

Official pharmacological data indicates that following oral administration, the onset of effect typically occurs between 15 and 60 minutes. The amount of medication in the bloodstream reaches its maximum concentration in approximately two hours. These timeframes indicate the rate at which the drug begins to act in the body.


Q: What is the longest period of time Nexit is usually taken for?

Official regulatory documents state that the effectiveness of the drug for long-term use (defined as more than four months) has not been assessed by systematic clinical studies. For long-term continued use, the official prescribing information requires that the usefulness of the drug be periodically reassessed.


Q: Is it necessary to use Nexit every day?

The administration schedule for Nexit is highly dependent on the condition being addressed. The medication may be prescribed in a single dose for sedation or in divided doses up to four times per day for anxiety or pruritus. The variation in administration schedules shows that the medication may be prescribed for single doses or daily divided doses, depending on the need.


Q: Does Nexit typically cause weight gain or weight loss?

Weight changes are not formally listed as a common, uncommon, or rare adverse reaction in the drug's official safety profile, as documented in regulatory sources. The official adverse reaction tables focus on reactions such as sedation, dry mouth, and fatigue.


Q: Are there any long-term health concerns associated with using Nexit?

Official regulatory documents note that the drug's effectiveness has not been assessed in studies longer than four months. Furthermore, the safety label highlights the risk of QT-interval prolongation, a serious cardiac safety consideration that influences its appropriate use over time.


Q: Does Nexit interact with common over-the-counter pain relievers?

Regulatory labels do not specifically name non-opioid, non-sedating over-the-counter (OTC) pain relievers. However, the official document includes a general warning of potentiation when used with any other Central Nervous System (CNS) depressant. This caution is directed toward products that may also have CNS depressant effects.


Q: Are there any specific foods or drinks that should be avoided when using Nexit?

Regulatory documents indicate the drug can be taken with or without food. However, official warnings strictly caution against the potentiating action of Nexit when used in conjunction with alcohol. Combining the two can cause excessive sedation and CNS depression.


Q: What is the risk of having an allergic reaction to Nexit?

Official prescribing information states that hypersensitivity to Nexit (Hydroxyzine) or its active metabolites is a formal contraindication for use. Additionally, rare, severe skin reactions, such as Acute Generalized Exanthematous Pustulosis (AGEP), have been reported in postmarketing experience.


Q: Does Nexit affect a person's ability to drive or operate machinery?

Due to the listed very common side effect of drowsiness (sedation), official regulatory information requires that patients be warned of this possibility. Official regulatory information includes a warning that patients should be aware of this possibility and avoid driving or operating dangerous machinery due to the risk of impairment.


Q: Is Nexit considered appropriate for children or adolescents?

Regulatory criteria permit the use of Nexit in both adults and children for specific, defined indications. Use in children involves specific considerations, including weight-based use, which are detailed in the official prescribing documentation. Adolescents are included in the pediatric population for these uses.


Q: Does Nexit have a potential for dependence or withdrawal if stopped suddenly?

Nexit is not listed as a controlled substance. However, regulatory information notes that if the medicine is discontinued, symptoms of the underlying condition may return. Some patients have also reported withdrawal-like effects such as dizziness, tremors, and insomnia.


Q: Is Nexit available as a generic medicine?

Yes. The active ingredient in Nexit is hydroxyzine, and various generic versions of hydroxyzine have been approved by the FDA. These forms are widely available as the hydrochloride and pamoate salts for oral administration.


Q: Why is Nexit sometimes prescribed alongside other medications?

Regulatory documents indicate that Nexit is specifically prescribed as an adjunctive medication in certain medical contexts. For example, in pre- and post-operative sedation, it is used to help permit reduction in the required dosage of narcotics prescribed concurrently.


Q: Is Nexit a recently approved medicine?

No. The initial approval of the active ingredient, hydroxyzine, occurred several decades ago. Therefore, according to official records, it is not considered a recently approved medicine by health authorities.


Q: Can Nexit affect my mood or sleep patterns?

Yes, Nexit can affect both. Sedation is listed as a very common side effect and can impact sleep, particularly when treatment begins. Other documented effects on the central nervous system include dizziness, disorientation, and, in rare instances, hallucination.


Q: What should I do if I think Nexit is not helping my condition?

The official label requires that the usefulness of the drug be periodically reassessed by a prescribing physician, especially if long-term use is continued. This process helps ensure the drug remains appropriate for the condition.


Q: Does Nexit affect blood pressure or heart rate?

Yes, Nexit can affect the heart. Tachycardia (increased heart rate) is listed as an adverse reaction. Serious, rare events listed include QT-interval prolongation and a severe heart rhythm abnormality known as Torsade de Pointes. Hypotension (low blood pressure) has also been reported in cases of overdose.


Q: Can Nexit be cut in half or crushed?

Official regulatory documents do not provide specific instructions for physically altering the solid dosage forms (tablets or capsules). The medication is also available as a liquid syrup or oral solution. If swallowing a solid form presents difficulty, the liquid syrup or oral solution form is available for administration.


Q: What medical tests are sometimes required before or during Nexit use?

A prescribing physician is required to rule out a pre-existing prolonged QT interval and other risk factors for serious heart rhythm issues before Nexit is initiated. Additionally, official documents recommend monitoring Cyclosporine concentrations if that medicine is being co-administered.


Q: Does Nexit have any restrictions regarding alcohol consumption?

Yes. Regulatory documents strictly warn about using Nexit with alcohol. This is due to the risk that combining the two can potentiate (increase) the sedative effects, leading to excessive Central Nervous System (CNS) depression and impairment.


Q: Is it normal to feel [mild, common side effect] when starting Nexit?

Yes. Official information notes that the most common side effect, drowsiness (sedation), is usually transitory (temporary). This effect may lessen or disappear after a few days of continued use, or if the prescribed amount is lowered.


Q: Does Nexit have an impact on dental health?

One of the very common side effects listed in regulatory documents is Dry Mouth (an anticholinergic effect). The presence of dry mouth is a factor that can potentially affect dental health.


Q: Can Nexit be taken if I have a history of seizures?

Official information advises that caution is required for use in patients with a history of seizure disorders or epilepsy. Rare instances of involuntary motor activity, including convulsions, have been documented.


Q: What is the difference between the active and inactive ingredients in Nexit?

The active ingredient is Hydroxyzine, which is the component responsible for the drug's therapeutic effect. The inactive ingredients include various materials (such as fillers, dyes, and coatings) that are necessary for the medicine's form and stability but do not contribute to its effect on the body.


Q: Does Nexit affect fertility?

Regulatory documents include a risk designation indicating potential concerns regarding fertility and fetal development, based on animal studies. This is consistent with its formal contraindication for use during early and late stages of pregnancy.


Q: If I switch from a different drug to Nexit, what should I be aware of?

Regulatory documents define constraints regarding potential drug interactions, particularly with other medicines that prolong the QT/QTc interval or any other Central Nervous System (CNS) depressants. Concomitant use with other CNS depressants may require dose reduction, as detailed in the official prescribing information.


Q: How is Nexit eliminated from the body?

Nexit is metabolized (broken down) primarily in the liver to form its main active metabolite, cetirizine. Approximately 70% of this active metabolite is then excreted unchanged in the urine by the kidneys.


Q: Does Nexit interact with caffeine?

Official information does not list caffeine, but regulatory documents caution that the effects of Central Nervous System (CNS) depressants, like Nexit, and CNS stimulants may counteract or modify one another's action if used together.


Q: Is Nexit designed to cure the condition or manage the symptoms?

Official regulatory documents and indications describe the drug's purpose as providing symptomatic relief and management. Its approved uses are to alleviate itching and reduce anxiety and tension, suggesting its role is to treat the manifestations of the condition rather than providing a cure.


Q: What clinical trials led to the approval of Nexit?

Studies conducted to support the use of Nexit are described in regulatory documents as short-term controlled trials in patients with anxiety and itching. These studies focused on measuring changes in standardized scoring tools. The patient-facing label generally describes the type of evidence rather than listing the specific trial names or identifiers.

How should Nexit be stored and disposed of?

The official labeling for Nexit (Hydroxyzine) requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with brief temperature excursions permitted up to 30 C.

  • Protection: The medicine must be protected from light, moisture, and freezing (especially liquid forms) to preserve its stability. It must be kept in a tightly closed, original container.
  • Child Safety: It is mandatory to keep this and all medications out of the sight and reach of children.
  • Disposal: Unused or expired Nexit must be discarded according to local regulations. Do not dispose of the medication by flushing it down the toilet or pouring it down a drain, unless specifically instructed to do so by a healthcare professional or an official take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nexit found in:

A-Z Index: